A new report from a bipartisan psychedelics caucus in Congress summarizes stakeholders’ views on how the therapeutic use of substances like psilocybin, ibogaine and DMT can be “safely and ethically integrated” into the U.S. healthcare system, emphasizing the need for collaboration across federal agencies and with states.
The document, published on Thursday by the Congressional Psychedelics Advancing Therapies (PATH) Caucus, comes after lawmakers in 2024 issued a request for information (RFI) seeking input from experts about how to best set up a regulatory framework for psychedelic medicines.
An analysis of responses to the RFI found “broad consensus among clinicians, researchers, veteran advocates, Tribal leaders, payors, regulators, and patients that [psychedelic-assisted therapy] could offer safe, equitable, and evidence‑based treatment for a wide array of treatment-resistant conditions,” a press release from the caucus says about the new report.
The report itself, however, cautions that there are “areas of agreement, tension, concern, and hope that require consideration, discussion, and further input to ensure that actions going forward are supported by policies related to safe access and participant and patient protections in PAT research.”
“These policies must ensure that the potential benefits are based on patient needs and minimally restricted by geography across the U.S.
Read full article on Marijuana Moment
